1. A carrier for delivering a substance to extracellular matrix-producing cells in the lungs containing a retinoid as a directing agent. ! 2. The carrier according to claim 1, where the retinoid derivative contains retinol. ! 3. The carrier according to claim 1 or 2, where the content of the retinoid is 0.2-20 wt.% Of the total carrier. ! 4. The carrier according to claim 1 or 2, where the carrier is in the form of a liposome, and the molar ratio of retinoid to lipid contained in the liposome is 8: 1-1: 4. ! 5. Composition for the treatment of pulmonary fibrosis, containing a carrier according to any one of claims 1 to 4 and a drug that controls the activity or growth of extracellular matrix-producing cells in the lungs. ! 6. The composition according to claim 5, where the drug, which controls the activity or growth of extracellular matrix-producing cells in the lungs, is selected from the group consisting of an agent for inhibiting the activity or producing a bioactive substance selected from the group consisting of gelatinase A, gelatinase B and angiotensinogen, an inhibitor of cell activity, a growth inhibitor, an apoptosis inducing agent, as well as siRNA, ribozyme, antisense nucleic acid, DNA / RNA of a chimeric polynucleotide that targets at least it least one of the molecules constituting the extracellular matrix, or molecules involved in the production or secretion of said molecules, extracellular matrix components, and a vector that expresses said siRNA, ribozyme, anti-sense nucleic acid, and DNA / RNA chimeric polynucleotide. ! 7. The composition according to claim 6, where the molecule involved in the production or secretion of constituents of the extracellular matrix of molecules is HSP47. ! 8. Composition1. Носитель для доставки вещества к продуцирующим внеклеточный матрикс клеткам в легких, содержащий ретиноид в качестве направляющего агента. ! 2. Носитель по п.1, где производное ретиноида содержит ретинол. ! 3. Носитель по п.1 или 2, где содержание
